Patient Voice

743 A Patient’s Perspective on Benzodiazepines, Co-Dispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
Cher Thomas
See related article on page 794.

Editorials

745 Environmental Risks to Kidney Health
James S. Kaufman
See related article on page 766.

747 Can COMBINED Magnetic Resonance Imaging Measure the Progression of Kidney Disease?
Menno Pruijm
See related article on page 776.

750 Donor Characteristics and Short-Term Kidney Allograft Outcomes: Opportunities to Expand Utilization
John J. Friedewald and Bing Ho
See related article on page 813.

752 Will Universal Access to Health Care Mean Equitable Access to Kidney Transplantation?
Meera N. Harhay and Patrick B. Mark
See related article on page 830.

Original Articles

Chronic Kidney Disease

755 Low Serum Bicarbonate and CKD Progression in Children
Denver D. Brown, Jeniﬁer Roem, Derek K. Ng, Kimberly J. Reidy, Juhi Kumar, Matthew K. Abramowitz, Robert H. Mak, Susan L. Furth, George J. Schwartz, Bradley A. Warady, Frederick J. Kaskel, and Michal L. Melamed

766 Environment-Wide Association Study of CKD
Jeonghwan Lee, Sohee Oh, Habyeong Kang, Sunmi Kim, Gowoon Lee, Lilin Li, Clara Tammy Kim, Jung Nam An, Yun Kyu Oh, Chun Soo Lim, Dong Ki Kim, Yon Su Kim, Kyungho Choi, and Jung Pyo Lee
See related editorial on page 745.

776 Kidney Functional Magnetic Resonance Imaging and Change in eGFR in Individuals with CKD
See related editorial on page 747.

Maintenance Dialysis

784 Plasma Endothelin-1 and Risk of Death and Hospitalization in Patients Undergoing Maintenance Hemodialysis
Ping Li, Insa M. Schmidt, Venkata Sabbisetti, Maria Clarissa Tio, Alexander R. Opotowsky, and Sushrut S. Waikar
794 Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis
Abimereki D. Muzaale, Matthew Daubresse, Sunjae Bae, Nadia M. Chu, Krista L. Lentine, Dorry L. Segev, and Mara McAdams-DeMarco
See related Patient Voice on page 743.

805 Intradialytic Hypotension and Cardiac Arrhythmias in Patients Undergoing Maintenance Hemodialysis: Results from the Monitoring in Dialysis Study
Finnian R. Mc Causland, Jim A. Tumlin, Prabir Roy-Chaudhury, Bruce A. Koplan, Alexandru I. Costea, Vijay Kher, Don Williamson, Saurabh Pokhariyal, and David M. Charytan, on behalf of the MiD Investigators and Committees

813 Donor Age, Cold Ischemia Time, and Delayed Graft Function
Ilkka Helanterä, Hassan N. Ibrahim, Marko Lempinen, and Patrik Finne
See related editorial on page 750.

822 Management of Active Surveillance-Eligible Prostate Cancer during Pretransplantation Workup of Patients with Kidney Failure: A Simulation Study
Uwe Bieri, Kerstin Hübel, Harald Seeger, Girish S. Kulkarni, Tullio Sulser, Thomas Hermanns, and Marian S. Wettstein

830 Inequity in Access to Transplantation in the United Kingdom
Rishi Pruthi, Matthew L. Robb, Gabriel C. Oniscu, Charles Tomson, Andrew Bradley, John L. Forsythe, Wendy Metcalfe, Clare Bradley, Christopher Dudley, Rachel J. Johnson, Christopher Watson, Heather Draper, Damian Fogarty, Rommel Ravanavan, and Paul J. Roderick, on behalf of the ATTOM Investigators
See related editorial on page 752.

843 Association of Socioeconomic Status and Comorbidities with Racial Disparities during Kidney Transplant Evaluation
Karly A. Murphy, John W. Jackson, Tanjala S. Purnell, Ashton A. Shaffer, Christine E. Haugen, Nadia M. Chu, Deidra C. Crews, Silas P. Norman, Dorry L. Segev, and Mara A. McAdams-DeMarco

852 The Effects of Intensive Blood Pressure Lowering on Markers of Mineral Metabolism in Persons with CKD in SPRINT

855 Disease Modeling To Understand the Pathomechanisms of Human Genetic Kidney Disorders
Elisa Molinari and John A. Sayer

873 A Case of Nephrotic Syndrome after Allogeneic Stem Cell Transplantation
Jonathan J. Hogan

876 How COVID-19 Has Changed the Management of Glomerular Diseases
Andrew S. Bomback, Pietro A. Canetta, Wooin Ahn, Syeda B. Ahmad, Jai Radhakrishnan, and Gerald B. Appel
Impending Shortages of Kidney Replacement Therapy for COVID-19 Patients

David S. Goldfarb, Judith A. Benstein, Olga Zhdanova, Elizabeth Hammer, Clay A. Block, Nina J. Caplin, Nathan Thompson, and David M. Charytan

Chronicle of a Death Foretold: Can Studying Death Help Us Care for the Living?

Dena E. Rifkin

Screening for Cancer in Patients with Glomerular Diseases

Emmanuelle Plaisier and Pierre Ronco

SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?

Michael Walsh

Outpatient Management of the Kidney Transplant Recipient during the SARS-CoV-2 Virus Pandemic

Shana E. Gleeson, Richard N. Formica, and Ethan P. Marin

Application of the 2017 KDIGO Guideline for the Evaluation and Care of Living Kidney Donors to Clinical Practice

Amit X. Garg, Andrew S. Levey, Bertram L. Kasiske, Michael Cheung, and Krista L. Lentine, on behalf of the KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors Work Group and Evidence Review Team

On the Cover

What is the diagnosis?

A 50-year-old male from Sudan, with a history of vitiligo and kidney failure secondary to hypertensive nephrosclerosis after a living unrelated donor kidney transplant 2 years prior, presented to the clinic for evaluation of a skin lesion. On examination, there was a smooth, multilobulated, pink, nontender nodule on the left fifth metatarsal head (left). A biopsy revealed phaeohyphomycosis caused by *Medicopsis romeroi*, as ascertained by culture. Two years later, he returned to the clinic reporting that his vitiligo had begun to spread to involve his upper back, head, and neck (center). A biopsy revealed keratinocytes with pale blue cytoplasm, multiple keratohyalin granules, and a thickened granular layer, features consistent with epidermodysplasia verruciformis (EDV) (right).

Key teaching points

Phaeohyphomycoses refer to cutaneous and subcutaneous infections caused by various groups of dematiaceous fungi (Revankar and Sutton 2010). Infection caused by *M. romeroi* in solid organ transplant recipients is rare but tends to affect people from West Africa and Asia. *M. romeroi* should be considered in immunosuppressed patients from these endemic areas and can be treated by surgical excision with or without coadjuvantive antifungals (Los-Arcos et al. 2019).

EDV, caused by β-type human papilloma virus, can result in a generalized eruption of flat topped warts and areas of cutaneous change that can resemble tinea versicolor in morphology. Acquired EDV has been reported in persons with HIV/AIDS and recipients of solid organ transplants (Rogers et al. 2009; Ovits et al. 2017). In acquired EDV, it is hypothesized that depressed cell-mediated immunity results in increased susceptibility to otherwise nonpathogenic β-type human papilloma virus types (Rogers et al. 2009). Acquired EDV can be treated by de-escalating immunosuppressive therapy.

Left image: Phaeohyphomycosis. Smooth, multilobulated, pink nodule.

Center image: Epidermodysplasia verruciformis. Hypopigmented macules and flat-topped thin papules with overlying fine scale. Note the linear array on lesions on the scalp, consistent with the Koebner phenomenon. The patient gave his consent for photography and publication.

Right image: Histology of epidermodysplasia verruciformis. Keratinocytes with pale blue cytoplasm, multiple keratohyalin granules, and a thickened granular layer (×20 magnification).

References


(Images and text provided by Vernon Joseph Forrester, Darren Guffey, Barrett Zlotoff, Mark Wick, and Mary Nolan, University of Virginia, Charlottesville, VA)